Sign In
Buy NBIX
$175.77
+1.62 (+0.93%)
At Close: Jul 24, 2026
What Makes Neurocrine (NBIX) a New Strong Buy Stock
01:01pm, Tuesday, 04'th Nov 2025
Neurocrine (NBIX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Envestnet Asset Management Inc. Boosts Stock Holdings in Neurocrine Biosciences, Inc. $NBIX
03:57am, Tuesday, 04'th Nov 2025
Envestnet Asset Management Inc. boosted its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ: NBIX) by 61.9% in the undefined quarter, according to its most recent disclosure with the SEC. The
Bessemer Group Inc. Has $349,000 Position in Neurocrine Biosciences, Inc. $NBIX
03:37am, Monday, 03'rd Nov 2025
Bessemer Group Inc. lowered its holdings in Neurocrine Biosciences, Inc. (NASDAQ: NBIX) by 58.9% in the undefined quarter, according to the company in its most recent filing with the Securities and Ex
Asset Management One Co. Ltd. Decreases Holdings in Neurocrine Biosciences, Inc. $NBIX
03:38am, Wednesday, 29'th Oct 2025
Asset Management One Co. Ltd. reduced its holdings in Neurocrine Biosciences, Inc. (NASDAQ: NBIX) by 39.6% during the undefined quarter, according to the company in its most recent Form 13F filing wit
Neurocrine Biosciences, Inc. (NBIX) Q3 2025 Earnings Call Transcript
09:31pm, Tuesday, 28'th Oct 2025
Neurocrine Biosciences, Inc. (NASDAQ:NBIX ) Q3 2025 Earnings Call October 28, 2025 4:30 PM EDT Company Participants Todd Tushla Kyle Gano - CEO & Director Matthew Abernethy - Chief Financial Officer E
Here's What Key Metrics Tell Us About Neurocrine (NBIX) Q3 Earnings
08:31pm, Tuesday, 28'th Oct 2025
While the top- and bottom-line numbers for Neurocrine (NBIX) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics co
Neurocrine Biosciences Beats Estimates But Wall Street Punishes The Stock
08:03pm, Tuesday, 28'th Oct 2025
Neurocrine Biosciences posts standout Q3 beat as INGREZZA and CRENESSITY drive 28% product sales growth.
Neurocrine Biosciences (NBIX) Q3 Earnings and Revenues Top Estimates
06:11pm, Tuesday, 28'th Oct 2025
Neurocrine Biosciences (NBIX) came out with quarterly earnings of $2.04 per share, beating the Zacks Consensus Estimate of $1.58 per share. This compares to earnings of $1.24 per share a year ago.
Neurocrine Biosciences Reports Third Quarter 2025 Financial Results
04:01pm, Tuesday, 28'th Oct 2025
Achieved Total Net Product Sales of $790 Million Representing 28% Year-Over-Year Growth INGREZZA® (valbenazine) Third-Quarter 2025 Net Product Sales of $687 Million Representing 12% Year-Over-Year Gr
Neurocrine Biosciences (NBIX) Projected to Post Earnings on Tuesday
02:48am, Sunday, 26'th Oct 2025
Neurocrine Biosciences (NASDAQ: NBIX - Get Free Report) will likely be releasing its Q3 2025 results after the market closes on Tuesday, October 28th. Analysts expect Neurocrine Biosciences to post ea
Are You Looking for a Top Momentum Pick? Why Neurocrine Biosciences (NBIX) is a Great Choice
01:01pm, Friday, 24'th Oct 2025
Does Neurocrine Biosciences (NBIX) have what it takes to be a top stock pick for momentum investors? Let's find out.
3 Reasons Why Growth Investors Shouldn't Overlook Neurocrine (NBIX)
01:46pm, Thursday, 23'rd Oct 2025
Neurocrine (NBIX) possesses solid growth attributes, which could help it handily outperform the market.
Envestnet Portfolio Solutions Inc. Acquires 645 Shares of Neurocrine Biosciences, Inc. $NBIX
04:40am, Thursday, 23'rd Oct 2025
Envestnet Portfolio Solutions Inc. increased its holdings in Neurocrine Biosciences, Inc. (NASDAQ: NBIX) by 24.5% during the undefined quarter, according to its most recent Form 13F filing with the SE
2,718 Shares in Neurocrine Biosciences, Inc. $NBIX Bought by Sequoia Financial Advisors LLC
04:18am, Wednesday, 22'nd Oct 2025
Sequoia Financial Advisors LLC acquired a new stake in Neurocrine Biosciences, Inc. (NASDAQ: NBIX) in the second quarter, according to the company in its most recent 13F filing with the SEC. The insti
Neurocrine Biosciences (NBIX) Reports Next Week: Wall Street Expects Earnings Growth
11:06am, Tuesday, 21'st Oct 2025
Neurocrine (NBIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
